The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain
Abstract
Background: Duloxetine has demonstrated analgesic effect in chronic pain states. This study assesses the efficacy of duloxetine in chronic low back pain (CLBP). Methods: Adult patients with non‐radicular CLBP entered this 13‐week, double‐blind, randomized study comparing duloxetine 20, 60 or 120 mg once daily with placebo. The primary measure was comparison of duloxetine 60 mg with placebo on weekly mean 24‐h average pain. Secondary measures included Roland‐Morris Disability Questionnaire (RMDQ‐24), Patient’s Global Impressions of Improvement (PGI‐I), Brief Pain Inventory (BPI), safety and tolerability. Results: Four hundred four patients were enrolled, 267 completed. No significant differences existed between any dose of duloxetine and placebo on reduction in weekly mean 24‐h average pain at end‐point. Duloxetine 60 mg was superior to placebo from weeks 3–11 in relieving pain, but not at weeks 12–13. Duloxetine 60 mg demonstrated significant improvement on PGI‐I, RMDQ‐24, BPI‐average pain and BPI‐average interference. Significantly more patients taking duloxetine 120 mg (24.1%) discontinued because of adverse events, versus placebo (8.5%). Conclusions: Duloxetine was superior to placebo on the primary objective from weeks 3–11, but superiority was not maintained at end‐point. Duloxetine was superior to placebo on many secondary measures, and was well‐tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
A Study of the Natural History of Back Pain: Part I
ROLAND, M., & MORRIS, R. (1983) · Spine · doi:10.1097/00007632-198303000-00004 · Cited by 3,395 · cited 2×
“The secondary efficacy objectives included comparison of duloxetine 20 mg/day and 120 mg/day with placebo on the reduction in average weekly pain, and evaluation of all doses versus placebo on Patient s Global Impressions of Improvement (PGI-I) [16], 24- item Roland-Morris Disability Questionnaire (RMDQ24)[17], weekly…”
MethodDagenais, S., Caro, J., & Haldeman, S. (2008) · The Spine Journal · doi:10.1016/j.spinee.2007.10.005 · Cited by 2,046
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00095-7 · Cited by 1,754 · cited 2×
“The secondary efficacy objectives included comparison of duloxetine 20 mg/day and 120 mg/day with placebo on the reduction in average weekly pain, and evaluation of all doses versus placebo on Patient s Global Impressions of Improvement (PGI-I) [16], 24- item Roland-Morris Disability Questionnaire (RMDQ24)[17], weekly…”
MethodDeyo, R. A., & Weinstein, J. N. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440508 · Cited by 1,675
Clinically important outcomes in low back pain
Ostelo, R. W. J. G., & de Vet, H. C. W. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.03.003 · Cited by 840
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has demonstrated efficacy in the treatment of major depressive disorder (MDD) [7–9], generalized anxiety disorder [10], diabetic peripheral neuropathic pain (DPNP) [11–13] and fibromyalgia [14,15].”
BackgroundSelf-citationArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has demonstrated efficacy in the treatment of major depressive disorder (MDD) [7–9], generalized anxiety disorder [10], diabetic peripheral neuropathic pain (DPNP) [11–13] and fibromyalgia [14,15].”
BackgroundSelf-citationDetke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Self-citation
Cited by
Qaseem, A., Wilt, T. J., McLean, R. M., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-2367 · Cited by 3,234
Chou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2458 · Cited by 864
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Diagnosis and Management of Lumbar Spinal Stenosis: A Review
Katz, J. N., Zimmerman, Z. E., Mass, H., & Makhni, M. C. (2022) · JAMA · doi:10.1001/jama.2022.5921 · Cited by 562
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
Metadata
- Authors
- Skljarevski, V., Ossanna, M., Liu‐Seifert, H., Zhang, Q., Chappell, A., Iyengar, S., Detke, M., & Backonja, M.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2009-08-07
- Volume
- 16
- Issue
- 9
- Pages
- 1041-1048
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2135432810
- Cited by
- 165
- References
- 11
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. https://app.cochat.ai/papers/10.1111/j.1468-1331.2009.02648.x
- The paper
- Skljarevski, V., Ossanna, M., Liu‐Seifert, H., Zhang, Q., Chappell, A., Iyengar, S., Detke, M., & Backonja, M. (2009). A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2009.02648.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.